Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health, and in refractory/relapsed AML patients. Additionally, BP1001-A is being assessed in a Phase 1 study in refractory/relapsed patients with solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML.
Company Details
- Employees
- 7
- Address
- 4710 Bellaire Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.biopathholdings.com/
- HQ
- Bellaire, Texas
Bio-Path Holdings Questions
Bio-Path Holdings's website is https://www.biopathholdings.com/
Bio-Path Holdings's LinkedIn profile is https://www.linkedin.com/company/bpth
Bio-Path Holdings has
7 employees.
View email and phone details for 7
employees at Bio-Path Holdings.
Bio-Path Holdings's industry is
Biotechnology Research
Bio-Path Holdings's top competitors are
Zyversa Therapeutics Inc.,
Biorestorative Therapies, Inc.,
Immunic Therapeutics,
Salarius Pharmaceuticals,
Allurion Technologies,
Vivani,
Entera Bio Ltd.,
Aardvark Therapeutics,
Biomea Fusion,
Mbx Biosciences, Inc..
Bio-Path Holdings's categories are Biotechnology Research
